Product Development and Labeling

EAS’s strategic consulting service will provide solutions to companies confronting daunting product development and labeling issues by taking a holistic approach that considers a company’s marketing objectives and the current regulatory, compliance, and enforcement environment at the federal, state and local levels. The service is most often provided by a small team of expert consultants with complementary backgrounds.

Clients are guided through the various regulatory processes at each level of government including government affairs strategies, how to best effectuate policy changes and file official comments as necessary.

Our consultants help address questions such as: Should your company disclose GMO ingredients, create a “non-GMO” product line, or stay the course? What are the risks of self-defining “natural” foods including the risk of class action litigation challenging such claims? How can your company make undefined claims such as “Handcrafted” while minimizing risk from federal and state regulatory authorities and more?

Let EAS help develop proactive solutions for:



GMO Labeling



“Natural” Foods and Claims



Undefined Claims



New Threats Posed by FDA Warning Letters



FTC v. FDA



Trending Claims



Nutrition Facts Panel



Supplement Facts Panel



Competitive Challenges



Crisis Management



Long-Term Planning



Submissions Assistance



In-House Training

FDA Issues Draft Guidance on Container Closure Systems for Human Drugs and Biological Products

FDA has issued draft guidance with updated CMC and quality recommendations for container closure systems used with human drugs and biological products.

FDA Finalizes Food Safety Guidance for Ready-to-Eat Fresh-Cut Produce Operations

FDA Proposes Mandatory GRAS Notifications for Human and Animal Food Substances

FDA and NOAA Update Certification Procedures for Seafood Exported to the European Union

FDA Releases Agenda and Opens Public Docket for Listeria monocytogenes Prevention Meeting

FDA has released the agenda and opened a 90-day public docket for its August 2026 Public Meeting on Listeria monocytogenes Prevention, covering ready-to-eat foods, retail food safety, and emerging prevention strategies.

FDA’s Proposed GRAS Rule Clears White House Review

OMB review is one of the final procedural steps before publication of a proposed federal regulation. As FDA moves forward with its proposed GRAS rule, industry stakeholders should carefully review the proposal once released and evaluate any potential implications for their regulatory and product development activities.

The #1 FSMA Element Most Produce Importers Fail to Get Right

Many produce importers overlook one of the most frequently cited FSVP requirements: documenting supplier evaluations that demonstrate compliance with FDA’s Produce Safety Rule. Learn what FDA expects and how to strengthen your FSVP before an inspection.

Need Regulatory Support?

Start the Conversation Today

CONNECT WITH EAS